Home > Project Types > CEA/CUA > Casado LF, Hernández JA, Jarque I, Echave M, Casado MA, Castro A

Casado LF, Hernández JA, Jarque I, Echave M, Casado MA, Castro A

Casado LF, Hernández JA, Jarque I, Echave M, Casado MA, Castro A

 

 

Cost-utility of idelalisib in combination with rituximab in relapsed or refractory chronic lymphocytic leukemia
20th Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Glasgow, Scotland. 4-8 nov 2017

POSTER